Gastroenterology prior authorization at Regence
PA workflow, documentation criteria, and peer-to-peer prep — for prescribers and PA staff
Regence gastroenterology PA at a glance
Regence reviews gastroenterology PA submissions against its medical policy library, with rules drawn primarily from AGA / ACG / Cochrane IBD guidelines + STRIDE-II treat-to-target. Regence-specific context: BCBS licensee operating in Oregon, Washington (Clark/Cowlitz counties), Idaho, and Utah (~3.1M members). Subsidiary of Cambia Health Solutions. Prime Therapeutics PBM. Each state's DOI handles complaints for policies issued in that state.
Documentation packet — what to send
- IBD diagnosis confirmed by endoscopy/biopsy
- Disease distribution and severity
- Prior conventional therapies tried
- Steroid course (drug, dose, taper attempts)
- Therapeutic drug monitoring labs where applicable
- Tuberculosis + hepatitis B screening prior to biologic
Common denial patterns to pre-empt
Patterns observed in gastroenterology across payers, and where Regence's book of business overlaps:
- Step therapy through 5-ASA / immunomodulators / steroids first
- Switching between mechanism-of-action classes without documented failure
- Therapeutic drug monitoring not done before dose escalation
- Endoscopic disease not documented
- Step therapy via Prime Therapeutics
Appeal angles when Regence denies
- AGA / ACG guidelines for IBD positioning
- Endoscopic Mayo subscore or SES-CD documenting active disease
- Failure of prior biologic by mechanism of action (anti-TNF, anti-integrin, anti-IL-12/23, JAK)
- Steroid-dependence or steroid-refractory disease
Peer-to-peer prep
- Pull the most recent endoscopy report with photos if possible
- Quantify steroid dependence (mg of prednisone per year, taper attempts)
- Reference STRIDE-II treat-to-target if requesting mechanism switch
- Cite specific endoscopic scoring (Mayo, SES-CD) and the date
Drug-specific PA criteria at Regence
Deep dives on each drug's PA criteria at Regence:
Frequently asked questions
What documentation does Regence need for gastroenterology prior authorizations?
Regence's PA packet for gastroenterology typically includes: IBD diagnosis confirmed by endoscopy/biopsy; Disease distribution and severity; Prior conventional therapies tried; Steroid course (drug, dose, taper attempts). AGA / ACG / Cochrane IBD guidelines + STRIDE-II treat-to-target citations strengthen the submission.
What's the turnaround at Regence?
Regence standard decision: 30 days. Expedited (urgent care): 72 hours per 45 CFR §147.136. Internal appeal window if denied: 180 days.
Which gastroenterology drugs does Regence most often PA-restrict?
Top targets in gastroenterology: adalimumab, infliximab, ustekinumab, risankizumab, tofacitinib. Each follows the per-drug step therapy + documentation requirements published in Regence's medical policy library.
How do I prep a peer-to-peer with Regence in gastroenterology?
Pull the most recent endoscopy report with photos if possible Quantify steroid dependence (mg of prednisone per year, taper attempts) Have the policy URL and the patient's chart open before the call.
Generate a Gastroenterology PA packet
Open ApprovalHelp — generate a gastroenterology PA packet tailored to Regence's criteria, with prescriber attestation and supporting citations pre-filled.
Get started →Contact: hello@approvalhelp.com